| dc.relation | Chevallard M, Belloli L, Ughi N, Adinolfi A, Casu C, Di Cicco M, et al. Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting. Rheumatol Int. 2021;41(7):1253–61. https://doi.org/10.1007/s00296-021-04863-x 2. Kim Y, Ahn E, Lee S, Lim DH, Kim A, Lee SG, et al. Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic. J Korean Med Sci. 2020;35(48):e423. doi: 10.3346/jkms.2020.35.e423 3. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020;19(5):102523. https://doi.org/10.1016/j.autrev.2020.102523 4. Zhao S, Chen H. Effectiveness of health education by telephone follow-up on self-efficacy among discharged patients with rheumatoid arthritis: A randomised control trial. J Clin Nurs. 2019;28(21–22):3840–7. doi: 10.1111/jocn.15002. Epub 2019 Aug 1 5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. doi: 10.1056/NEJMoa2001017 6. Duan G. Intuition on virology, epidemiology, pathogenesis, and control of COVID-19. Nov Res Microbiol J. 2020;4(5):955–67. https://dx.doi.org/10.21608/nrmj.2020.118446 7. Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. J Transl Med. 2020;18(1):1–9. https://doi.org/10.1186/s12967-020-02520-8 8. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324(8):782–93. doi: 10.1001/jama.2020.12839 9. Galanopoulos M, Gkeros F, Doukatas A, Karianakis G, Pontas C, Tsoukalas N, et al. COVID-19 pandemic: Pathophysiology and manifestations from the gastrointestinal tract. World J Gastroenterol. 2020;26(31):4579–88. doi: 10.3748/wjg.v26.i31.4579 10. Myrstad M, Ihle-Hansen H, Tveita AA, Andersen EL, Nygård S, Tveit A, et al. National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - A prospective cohort study. Scand J Trauma Resusc Emerg Med. 2020;28(1):1–8. doi: 10.1186/s13049-020-00764-3 11. Asano T, Immunol S, Asano T, Boisson B, Onodi F, Matuozzo D, et al. X-linked recessive TLR7 deficiency in ~ 1 % of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6(62):eabl4348. doi: 10.1126/sciimmunol.abl4348 12. World Health Organization. Alocución de apertura del Director General de la OMS en la rueda de prensa sobre la COVID-19 celebrada el 11 de marzo de 2020 [Internet]. World Health Organization newsletter. 2020 [citedo 2021 Jul 23]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 13. Ruiz Gomez F. Ministerio de Salud y protección social - Resolucion 385 del 12 de marzo del 2020 [Internet]. Colombia; 2020 p. 1–5. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-385-de-2020.pdf 14. Coomes EA, Leis JA, Gold WL. Quarantine. CMAJ. 2020;192(13):E338. 15. Parmet W, Sinha M. Covid 19-The Law and Limits of Quarant. NEJM. 2020;382(15):e28. doi: 10.1056/NEJMp2004211 16. Ruiz Gomez F. Ministerio de Salud y protección social - Resolución 464 de 2020 [Internet]. Colombia; 202AD p. 1–3. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-464-de-2020.pdf 17. Ministerio de Salud y Protección Social. Coronavirus Colombia [Internet]. 2021. p. 1. Available from: https://coronaviruscolombia.gov.co/Covid19/index.html 18. Ministerio de Salud y Protección Social. Vacunación contra COVID-19 [Internet]. 2021. p. 1. Available from: https://www.minsalud.gov.co/salud/publica/Vacunacion/Paginas/Vacunacion-covid-19.aspx 19. Díaz-Rojas JA, Dávila-Ramírez FA, Quintana-López G, Aristizábal-Gutiérrez F, Brown P. Prevalencia de artritis reumatoide en Colombia: una aproximación basada en la carga de la enfermedad durante el año 2005. Rev Colomb Reumatol. 2016;23(1):11–6. doi: 10.1016/j.rcreu.2015.12.004 20. Londoño J, Peláez I, Cuervo F, Angarita I, Londo J, Giraldo R, et al. Prevalencia de la enfermedad reumática en Colombia , según estrategia COPCORD-Asociación prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reumatol. 2018;5(4):245–56. Doi: 10.1016/j.rcreu.2018.08.003 21. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320(13):1360-1372. doi: 10.1001/jama.2018.13103 22. Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Korpela M, Leirisalo-Repo M, et al. Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J Rheumatol. 2007;34(10):1987-1991 23. Maldonado G, Mieles M, Orellana P, Gratzia Ordoñez M, Valencia M, Paredes C, et al. Índices de evolucion de la ar. In: Curso Internacional de Reumatología y Rehabilitación del Pacífico IX Manta. 2014. 24. Poggenborg RP, Madsen OR, Dreyer L, Bukh G, Hansen A. Patient-controlled outpatient follow-up on demand for patients with rheumatoid arthritis: a 2-year randomized controlled trial. Clin Rheumatol. 2021;40(9):3599-3604. doi: 10.1007/s10067-021-05674-y 25. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, Van Der Heijde D, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1102–1107. doi: 10.1136/annrheumdis-2016-210711 26. Cáceres-Méndez Edwars A, Castro-Díaz Sergio M, Gómez-Restrepo C, Puyana JC. Telemedicina: historia, aplicaciones y nuevas herramientas en el aprendizaje. Univ Médica. 2011;52(1):11-35. 27. Zundel KM. Telemedicine: History, applications, and impact on librarianship. Bull Med Libr Assoc. 1996;84(1):71–9. 28. Lovett JE, Bashshur RL. Telemedicine in the USA. An overview. Telecomm Policy. 1979;3(1):3–14. 29. Springs P. Innovative New Technologies to Identify. 2010;16(3):373–81. 30. Social Ministerio de Salud y Protección. Resolución No. 2654 del 2019. 2019 [citado 2021 Jul 23]. Available from: https://www.minsalud.gov.co/Normatividad_Nuevo/Forms/DispForm.aspx?ID=5754 31. Secretaria Distrital de Salud B. Circular 015-Modificación Operativa Servicio Ambulatorio [Internet]. Secretaria distrital de salud. 2020 [citedo 2021 Jul 23]. Available from: http://www.saludcapital.gov.co/Paginas2/Coronavirus-documentos.aspx 32. Viceministerio de Salud Publica. Resolución 521 Procedimiento para atención de Población en aislamiento Preventivo Énfasis en población adulta mayor. [Internet]. 2020 [citedo 2021 Jul 23]. Available from: https://www.minsalud.gov.co/RID/resolucion-521-de-2020.pdf 33. World Health Organization. Global Observatory for eHealth Vol 2 Telemedicine: Opportunity and developments in Member States. World Heal Organ. 2010;2:96. 34. Portnoy J, Waller M, Elliott T. Portnoy J, Waller M, Elliott T. Telemedicine in the Era of COVID-19. J Allergy Clin Immunol Pract. 2020;8(5):1489-1491. doi: 10.1016/j.jaip.2020.03.008 35. Elera-Fitzcarrald C, Ugarte-Gil MF, Alarcón GS. COVID-19 and Its Potential Effect on Patients with Rheumatic Diseases in Latin America. J Clin Rheumatol. 2020;26(6):215–7. doi: 10.1097/RHU.0000000000001493 36. Laskowski ER, Johnson SE, Shelerud RA, Lee JA, Rabatin AE, Driscoll SW, et al. The Telemedicine Musculoskeletal Examination. Mayo Clin Proc. 2020 Aug;95(8):1715-1731. doi: 10.1016/j.mayocp.2020.05.026 37. Tornero-Molina J, Sánchez-Alonso F, Fernández-Prada M, Bris-Ochaita ML, Sifuentes-Giraldo A, Vidal-Fuentes J. Tele-Rheumatology During the COVID-19 Pandemic. Reumatol Clin (Engl Ed). 2021;S2173-5743(21)00117-9. doi: 10.1016/j.reumae.2020.10.002 38. de Thurah A, Stengaard-Pedersen K, Axelsen M, Fredberg U, Schougaard LMV, Hjollund NHI, et al. Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial. Arthritis Care Res. 2018;70(3):353–60. doi: 10.1002/acr.23280 39. Piga M, Cangemi I, Mathieu A, Cauli A. Telemedicine for patients with rheumatic diseases: Systematic review and proposal for research agenda. Semin Arthritis Rheum. 2017;47(1):121–8. http://dx.doi.org/10.1016/j.semarthrit.2017.03.014 40. Knudsen LR, de Thurah A, Lomborg K. Experiences With Telehealth Followup in Patients With Rheumatoid Arthritis: A Qualitative Interview Study. Arthritis Care Res (Hoboken). 2018;70(9):1366–72. doi: 10.1002/acr.23483 41. Taylor PC. Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheumatol. 2020;16(9):477–478. doi: 10.1038/s41584-020-0449-6 42. Wood PR, Caplan L. Outcomes, Satisfaction, and Costs of a Rheumatology Telemedicine Program: A Longitudinal Evaluation. J Clin Rheumatol. 2019;25(1):41–4. doi: 10.1097/RHU.0000000000000778 43. Ciurea A, Papagiannoulis E, Bürki K, Von Loga I, Micheroli R, Möller B, et al. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis. 2021;80(2):238–241. doi: 10.1136/annrheumdis-2020-218705 44. Ziadé N, Hmamouchi I, el Kibbi L, Abdulateef N, Halabi H, Abutiban F, et al. The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. Clin Rheumatol. 2020;39(11):3205–3213. doi: 10.1007/s10067-020-05428-2 45. Sauver JLS, Warner DO, Yawn BP, Jacobson J, Gree MEM, Pankratz JJ, et al. Why patients visit their doctors: assessing the most prevalent conditions in a defined US population. 2014;88(1):56–67. doi: 10.1016/j.mayocp.2012.08.020 46. Ingegnoli F, Cincinelli G, Luppino AF, Favalli EG, Orenti A, Boracchi P, et al. Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. Ann Rheum Dis. 2021;80(9):1243–1245. doi: 10.1136/annrheumdis-2021-220142 47. Piga M, Floris A, Congia M, Chessa E, Cangemi I, Cauli A. Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic. Rheumatology (Oxford). 2021;keab632. doi: 10.1093/rheumatology/keab632 48. Benavent D, Fernández-Luque L, Navarro-Compán V, Balsa A, Plasencia C. Comment on: Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization. Rheumatol Adv Pract. 2021;5(2):rkab032. doi: 10.1093/rap/rkab032 49. López-Medina C, Escudero A, Collantes-Estevez E. COVID-19 pandemic: An opportunity to assess the utility of telemedicine in patients with rheumatic diseases. Ann Rheum Dis. 2021;annrheumdis-2020-218008. doi: 10.1136/annrheumdis-2020-218008 50. Thiele T, Beider S, Kühl H, Mielke G, Holz A, Hirsch S, et al. Care of rheumatology patients during the lockdown in early 2020: Telemedicine, delegation, patient satisfaction and vaccination behavior. Z Rheumatol. 2021; 1-6. doi: 10.1007/s00393-021-01005-3 51. Maheswaranathan M, Chu P, Johannemann A, Criscione-Schreiber L, Clowse M, Leverenz DL. The Impact of the COVID-19 Pandemic and Telemedicine Implementation on Practice Patterns and Electronic Health Record Utilization in an Academic Rheumatology Practice. J Clin Rheumatol. 2021;Ah(00):1–4. doi: 10.1097/RHU.0000000000001751 52. Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? . Ann Rheum Dis. 2020;79(6):839-840. doi: 10.1136/annrheumdis-2020-21732 | |
